ATE371738T1 - Mittel und verfahren zur diagnose und behandlung affektiver störungen - Google Patents

Mittel und verfahren zur diagnose und behandlung affektiver störungen

Info

Publication number
ATE371738T1
ATE371738T1 AT04009160T AT04009160T ATE371738T1 AT E371738 T1 ATE371738 T1 AT E371738T1 AT 04009160 T AT04009160 T AT 04009160T AT 04009160 T AT04009160 T AT 04009160T AT E371738 T1 ATE371738 T1 AT E371738T1
Authority
AT
Austria
Prior art keywords
nucleic acid
acid molecules
present
methods
relates
Prior art date
Application number
AT04009160T
Other languages
English (en)
Inventor
Nicholas Barden
Inge Sillaber
Marcelo Paez-Pereda
Original Assignee
Affectis Pharmaceuticals Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affectis Pharmaceuticals Ag filed Critical Affectis Pharmaceuticals Ag
Application granted granted Critical
Publication of ATE371738T1 publication Critical patent/ATE371738T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/304—Mood disorders, e.g. bipolar, depression

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
AT04009160T 2003-04-17 2004-04-16 Mittel und verfahren zur diagnose und behandlung affektiver störungen ATE371738T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03008753 2003-04-17
EP03019626 2003-09-04

Publications (1)

Publication Number Publication Date
ATE371738T1 true ATE371738T1 (de) 2007-09-15

Family

ID=33300969

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04018640T ATE365798T1 (de) 2003-04-17 2004-04-16 Mittel und verfahren zur diagnose und behandlung affektiver störungen
AT04009160T ATE371738T1 (de) 2003-04-17 2004-04-16 Mittel und verfahren zur diagnose und behandlung affektiver störungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT04018640T ATE365798T1 (de) 2003-04-17 2004-04-16 Mittel und verfahren zur diagnose und behandlung affektiver störungen

Country Status (12)

Country Link
US (4) US20050147604A1 (de)
EP (2) EP1469072B1 (de)
JP (2) JP2006523648A (de)
AT (2) ATE365798T1 (de)
CA (1) CA2522985A1 (de)
DE (2) DE602004007184T2 (de)
DK (2) DK1473367T3 (de)
ES (2) ES2286543T3 (de)
MX (1) MXPA05011008A (de)
PL (2) PL1473367T3 (de)
PT (2) PT1473367E (de)
WO (1) WO2004092384A2 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4384852B2 (ja) 2001-01-17 2009-12-16 イントリート ピーティーワイ リミテッド 非機能性ｐ２ｘ７レセプター抗体、癌及びその他の容態の診断及び処置
US7344860B2 (en) 2003-04-03 2008-03-18 Bristol-Myers Squibb Company Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v
US8124730B1 (en) 2004-04-02 2012-02-28 Bristol-Myers Squibb Company Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v
MX2007002423A (es) * 2004-08-31 2007-08-07 Sylentis Sau Metodos y composiciones para inhibir la expresion del receptor p2x7.
EP2305258A3 (de) * 2005-05-31 2011-07-06 Duska Scientific Co Verhinderung von neuronalen schäden
WO2007115095A2 (en) * 2006-03-29 2007-10-11 The Trustees Of Columbia University In The City Ofnew York Systems and methods for using molecular networks in genetic linkage analysis of complex traits
US20070249666A1 (en) * 2006-03-31 2007-10-25 Bratcher Natalie A P2X7 Antagonists to Treat Affective Disorders
WO2008043146A1 (en) * 2006-10-10 2008-04-17 Biosceptre International Limited Antibodies against non functional p2x7 receptor
JP2010505426A (ja) * 2006-10-10 2010-02-25 バイオスセプター インターナショナル リミテッド 非機能性ｐ２ｘ７受容体に対する抗体を産生するハイブリドーマ
EP1938801A1 (de) 2006-12-22 2008-07-02 Biofrontera Bioscience GmbH Nanoemulsion
WO2009019503A2 (en) * 2007-08-03 2009-02-12 Astrazeneca Ab P2x7 antagonists for use in the treatment of mood disorders
ATE542139T1 (de) 2007-09-14 2012-02-15 Biosceptre Int Ltd Purinerge (p2x)-rezeptoren in extrazellulärer körperflüssigkeit
ES2619681T3 (es) 2007-09-14 2017-06-26 Biosceptre (Aust) Pty Ltd Novedosos epítopos P2X7
US20100204247A1 (en) * 2007-10-04 2010-08-12 Duffy Joseph L N-substituted oxindoline derivatives as calcium channel blockers
CN102143978B (zh) 2008-07-04 2015-02-18 生物权威国际有限公司 抗p2x7肽和表位
EP2467404B1 (de) 2009-08-20 2015-09-30 Biosceptre International Limited Antikörper gegen den p2x7-rezeptor und fragmente davon
WO2011075789A1 (en) 2009-12-24 2011-06-30 Biosceptre International Limited Antibodies to non-functional oligomeric p2x7 receptors
EP2613808B1 (de) 2010-09-10 2017-11-08 Biosceptre (Aust) Pty Ltd Haustier krebst therapien mit einem anti p2x7 antikörper
MX349321B (es) 2011-07-01 2017-07-21 Biosceptre (Aust) Pty Ltd Terapia combinada.
WO2014182601A1 (en) 2013-05-08 2014-11-13 Children's Medical Center Corporation A method of preventing and treating type 1 diabetes, allograft rejection and lung fibrosis (by targeting the atp/p2x7r axis)
JP6728657B2 (ja) * 2015-12-04 2020-07-22 東洋紡株式会社 核酸増幅法
US20190106747A1 (en) * 2016-03-21 2019-04-11 Indiana University Research And Technology Corporation Drugs, pharmacogenomics and biomarkers for acive longevity
US12060148B2 (en) 2022-08-16 2024-08-13 Honeywell International Inc. Ground resonance detection and warning system and method
CN115381950B (zh) * 2022-09-06 2023-08-18 天津医科大学总医院 Rab 35或其下游调控分子在治疗骨折后慢性疼痛中的应用
WO2024208433A1 (en) 2023-04-06 2024-10-10 Biofrontera Bioscience Gmbh Nanoemulsion without propylene glycol
WO2024208434A1 (en) 2023-04-06 2024-10-10 Biofrontera Bioscience Gmbh Pressurized nanoemulsion

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214581B1 (en) * 1998-01-16 2001-04-10 Abbott Laboratories Nucleic acids encoding a functional human purinoreceptor P2X3 and P2X6, and methods of production and use thereof
WO1999055901A2 (en) * 1998-04-30 1999-11-04 Abbott Laboratories Screening assay for identifying human purinoreceptor ligands
JP2000095695A (ja) * 1998-07-23 2000-04-04 Nippon Koutai Kenkyusho:Kk 精神分裂病治療薬
ATE294577T1 (de) * 1999-02-24 2005-05-15 Univ Cincinnati Verwendung von sulfamat derivaten zur behandlung von impulsiven störungen
CA2394428A1 (en) 1999-12-16 2001-06-21 Katayanagi Institute Method for detecting target nucleotide sequences
SE9904652D0 (sv) * 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
WO2001063294A2 (en) * 2000-02-24 2001-08-30 Oxford Glycosciences (Uk) Limited Diagnosis of bipolar affective disorder (bad) and unipolar depression
JP2002330787A (ja) * 2000-10-21 2002-11-19 Astrazeneca Ab 化学物質
JP2003135075A (ja) * 2001-11-05 2003-05-13 Research Association For Biotechnology 新規な全長ｃＤＮＡ
PA8557501A1 (es) * 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
WO2003042190A1 (en) * 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
CA2471562A1 (en) * 2001-12-21 2003-07-24 King Pharmaceuticals Research And Development, Inc. Tyrosyl derivatives and their use as p2x7 receptor modulators
US20040029841A1 (en) * 2002-04-18 2004-02-12 Renshaw Perry F. Purinergic antagonists for treating depression
US20050037983A1 (en) * 2003-03-11 2005-02-17 Timothy Dinan Compositions and methods for the treatment of depression and other affective disorders
US7344860B2 (en) * 2003-04-03 2008-03-18 Bristol-Myers Squibb Company Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v
US6759435B1 (en) * 2003-07-03 2004-07-06 A.P. Group Inc. Antidepressant drugs and methods
FR2867784B1 (fr) 2004-03-17 2006-06-09 Commissariat Energie Atomique Aptameres selectionnes a partir de cellules vivantes tumorales et leurs applications

Also Published As

Publication number Publication date
EP1473367B1 (de) 2007-06-27
DK1469072T3 (da) 2008-01-07
US20080057504A1 (en) 2008-03-06
JP2006523648A (ja) 2006-10-19
EP1469072B1 (de) 2007-08-29
WO2004092384A2 (en) 2004-10-28
JP2010011855A (ja) 2010-01-21
US7767398B2 (en) 2010-08-03
CA2522985A1 (en) 2004-10-28
DK1473367T3 (da) 2007-10-01
EP1473367A1 (de) 2004-11-03
EP1469072A2 (de) 2004-10-20
WO2004092384A3 (en) 2005-06-02
EP1469072A3 (de) 2004-11-24
ES2286543T3 (es) 2007-12-01
PT1469072E (pt) 2007-10-29
DE602004007184T2 (de) 2008-02-28
MXPA05011008A (es) 2006-03-08
DE602004008528D1 (de) 2007-10-11
PL1469072T3 (pl) 2008-03-31
DE602004008528T2 (de) 2008-05-21
US20060110385A1 (en) 2006-05-25
US20050147604A1 (en) 2005-07-07
ES2293114T3 (es) 2008-03-16
DE602004007184D1 (de) 2007-08-09
PT1473367E (pt) 2007-09-10
US20080200411A1 (en) 2008-08-21
ATE365798T1 (de) 2007-07-15
PL1473367T3 (pl) 2007-11-30

Similar Documents

Publication Publication Date Title
ATE371738T1 (de) Mittel und verfahren zur diagnose und behandlung affektiver störungen
JP2008538238A5 (de)
EP1581656A4 (de) MODULATION DER EXPRESSION VON HIF1a UND HIF2a
DE602005019064D1 (de) Verfahren zur herstellung gefriergetrockneter blutplättchen, gefriergetrocknete blutplättchen enthaltende zusammensetzungen und verwendungsverfahren
MXPA02012747A (es) Moleculas del receptor de linfopoietina estromica timica y sus usos.
EA200700708A1 (ru) Мемантин для лечения расстройств поведения детского возраста
WO2010011283A3 (en) Fus/tls-based compounds and methods for diagnosis, treatment and prevention of amyotrophic lateral sclerosis and related motor neuron diseases
EP1987165A4 (de) Gene mit einfluss auf die menschliche gedächtnisleistung
ATE378423T1 (de) Polymorphismen des menschlichen hpxr gens und ihre anwendung in diagnose und therapie
ATE465408T1 (de) Verfahren zur diagnose und überwachung von neurologischen erkrankungen durch nachweis eines encephalotoxins
HK1042523A1 (zh) 青光眼和有關疾病的核酸、工具和其診斷、預後和治療的方法
DE602007008393D1 (de) Mittel und verfahren zur diagnose und behandlung von krebs auf basis des frmd3-gens
Araya et al. Interferon signaling modulates Down syndrome-associated Alzheimer’s disease pathology in a mouse model
WO2003087408A3 (en) Schizophrenia associated genes
DE60018964D1 (de) Diagnose und behandlung von krebs unter verwendung von sgp28-ähnlichen molekülen
ATE460673T1 (de) Screeningverfahren zum identifizieren protektiver substanzen für die behandlung neurodegenerativer und/oder ischämischer erkrankungen
WO2005094267A3 (en) Methods for regulating differentiation of neural cells and uses thereof
ATE522625T1 (de) Verfahren und zusammensetzungen zur diagnose und behandlung von lungenkrebs mittels pdgfra-, kit- oder kdg-gen als genmarker
Hasselmann Generation and application of a chimeric model to examine human microglia responses to amyloid pathology
DE60140934D1 (de) Polymorphismen des humanen cyp2b6 gens und deren verwendung in diagnostischen und therapeutischen anwendungen
WO2007039232A3 (en) Means and methods for diagnosing atgl related disorders
Shireby Regulatory genomic consequences of polygenic risk burden for Alzheimer’s disease
SE9902489D0 (sv) Mutated Nurr1 gene
ATE449842T1 (de) Anti-bambi antikörper oder rna zur diagnose und therapie bei dickdarm- oder leberkrebs
ATE363075T1 (de) Verfahren zur diagnose und behandlung von metastasen und dafür nützliche zusammensetzung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1469072

Country of ref document: EP

REN Ceased due to non-payment of the annual fee